Magnetic Resonance Imaging (MRI) Guided Stereotactic Adaptive Radiotherapy for Targeting Abdominal Cancer

ConditionAbdominal Cancer

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18+

SponsorAustralasian Gastro-Intestinal Trials Group

About this trial

The aim of this study is to investigate the effect of MRI-guided adaptive stereotactic radiotherapy on local control, survival, and toxicity in the treatment of oligometastatic cancer to the abdomen.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Aged 18 years or older

Liver

Adrenal

Abdomino-pelvic lymph node

Disqualifiers

Contra-indication to MRI

Previous high dose radiotherapy to a site requiring stereotactic treatment (including SIRTEX). Further SABR treatment of lesions previously treated with SABR or high dose radiotherapy is not permitted in this trial.

Substantial overlap with a previously treated high dose (definitive or stereotactic dose) radiation volume.

Primary prostate cancer, carcinoid tumours, germ cell tumours, lymphoma, small cell tumours

Trial design

Design model

Parallel

Treatments tested in this trial

Intervention: MRI-Linac SABR
Procedure/Surgery
The treatment planning protocol follows the UK SABR Consortium Guidelines. Patients will be prescribed the maximum isotoxic dose achievable while meeting normal organ tolerances (normal liver, kidney, spinal cord, stomach, duodenum, small and large bowel, heart, lungs, chest wall). The lowest acceptable SABR doses are indicated in the dose range Table within the protocol. The maximum dose/fraction also indicates the maximum the dose can be escalated to for each adaptive session on the MRI-Linac.

Treatment groups

30 Participants

are divided into 2 treatment groups

Group A: Intervention: MRI-Linac SABRExperimental treatment 1 intervention

Group B: Control: Standard SABRNo intervention 0 interventions

Trial outcomes

Primary outcomes

Rate of local control (Local Response Rate).

To determine if patients treated with MRI guided stereotactic radiotherapy improves local control. Local control is defined as absence of progression in treated lesion(s) and will be measured via clinical progress imaging (and assessed using RECIST criteria).

Time frame

Clinical progress imaging every 3 months post radiotherapy treatment until 3 years post radiotherapy.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Australasian Gastro-Intestinal Trials Group

Lead sponsor

Trans Tasman Radiation Oncology Group

Collaborator

Source ClinicalTrials.gov

Apply now